ScripAmid an ongoing capital crunch, Chinese drug makers pursuing in-licensing models have arrived at a commercialization crossroads. Jump-started by frontrunner Zai Lab Ltd. ’s successful introduction of
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. OliX, Hansoh Ink Licensing Pact To Deve